Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Pfizer and Innovent Biologics Announce Landmark Global Collaboration for Oncology Pipeline, Valued Up to $10.5 Billion
In a significant move poised to accelerate the development of novel cancer treatments, global pharmaceutical giant Pfizer and leading Chinese…
Read More
Immunai’s Digital "Plumbing" Secures Third Expansion with AstraZeneca, Deepening AI Integration Across Clinical Pipeline
Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has announced its third significant…
Read More
The Hereditary Angioedema Pharmaceutical Landscape Poised for Unprecedented Expansion Driven by Late-Stage Pipeline and Emerging Technologies
The pharmaceutical landscape for hereditary angioedema (HAE) is on the cusp of a significant transformation, marked by an unprecedented surge…
Read More
Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology
Gilead Sciences has officially completed its acquisition of Tubulis, a prominent German biotechnology firm specializing in the development of next-generation…
Read More
Eli Lilly Acquires Engage Biologics for Up to $202 Million, Bolstering Its Genetic Medicine Pipeline with Innovative Non-Viral DNA Delivery Technology
Pharmaceutical giant Eli Lilly and Company has announced its agreement to acquire Engage Biologics, a California-based biotechnology firm, for a…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
Teva Pharmaceuticals Acquires Emalex Biosciences for $700 Million to Bolster Neurology Pipeline and Drive Growth Strategy
Teva Pharmaceuticals is set to significantly expand its presence in the neuroscience market with the acquisition of Emalex Biosciences, a…
Read More
